StreetAlpha.app
Home › Stocks › ANIP

Ani Pharmaceuticals Inc (ANIP)

Healthcare
$69.99
▼ −1.27%
LAST CLOSE · NOV 17

ANI Pharmaceuticals develops, makes, and sells prescription medicines, including rare disease, brand name, and generic drugs. It last closed at $69.99 on Nov 17, down 1.27% on the day. ANIP last reported earnings on Fri, Aug 7, 2026. The average 12-month price target from 2 analysts is $103.00 (+47.2% from the last close), with a high of $121.00 and a low of $85.00.

AI Auto Pilots
Is ANIP in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$1.0B
+25.9% vs a year ago
Net income
$116.8M
+188.0% vs a year ago
EPS (diluted)
$5.03
+214.4% vs a year ago
Free cash flow
$205.3M
19.7% margin
Balance sheet
Cash & equivalents
$420.8M
At Sep 30
Debt
$297.7M
At Sep 30
Shareholder equity
$637.1M
Buybacks
$19.2M
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $216.1M$216.1MFY2021FY2022: $316.4M$316.4MFY2022FY2023: $486.8M$486.8MFY2023FY2024: $614.4M$614.4MFY2024FY2025: $883.4M$883.4MFY2025

From ANIP's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Aug 7
2026 · Before the open (BMO)
Reported EPS
$1.82
vs $1.67 est. · beat
Year-ago EPS
—
Not on file
Options-implied move
±9.0%
Priced in before that report
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated ANIP in the past 90 days, not enough for a consensus
Average 12-month target
$103.00
▲ 47.2% upside

Based on 2 analysts who set a price target on ANIP in the past 90 days. The average target is $103.00, with a high of $121.00 and a low of $85.00, compared with the last close of $69.99.

Low $85.00Avg $103.00High $121.00
Blue marker: last close $69.99
Highest target$121.00
Average target$103.00
Lowest target$85.00
Latest rating changes
GuggenheimTarget raised
Nov 6Buy$119 → $121
OppenheimerInitiated
Sep 23Buy$85
GuggenheimMaintained
Aug 10Buy$119
Canaccord GenuityTarget lowered
Aug 10Hold$91 → $90
Canaccord GenuityInitiated
Jul 17Hold$91
DateFirmActionRatingPrice target
Nov 6GuggenheimTarget raisedBuy$119 → $121
Sep 23OppenheimerInitiatedBuy$85
Aug 10GuggenheimMaintainedBuy$119
Aug 10Canaccord GenuityTarget loweredHold$91 → $90
Jul 17Canaccord GenuityInitiatedHold$91
Loading…

Technical Analysis

ANIP · as of the Nov 17 close · updated after every close
Downtrend

The stock is 2% below its 20 day and 3% below its 50 day average. It is 10% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 45). The nearest support is the swing low (Oct 14) at $69.90, and the nearest resistance the Pivot at $70.19.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 3.3%/day
Key levels
$87.7652 week high+25.4%
$76.90200 day average+9.9%
$75.31100 day average+7.6%
$72.3050 day average+3.3%
$72.20Swing high (Nov 11)+3.2%
$71.2220 day average+1.8%
$70.73Pivot R1+1.1%
$70.19Pivot+0.3%
$69.99Last close
$69.90Swing low (Oct 14)−0.1%
$69.46Pivot S1−0.8%
$67.1452 week low−4.1%
Indicators
RSI (14)44.73Middle of its rangeNeutral
MACD-0.59Above its signal lineBullish
Stochastic41.0Middle of its rangeNeutral
ADX (14)10.3No clear trend
Williams %R-67.9Oversold below −80, overbought above −20Neutral
CCI (20)-78.4Oversold below −100, overbought above 100Neutral
Rate of change−3.2%Change over 10 sessionsBearish
ATR (14)$2.28Typical daily range, 3.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ANIP

What happened before

See how ANIP did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ANIP usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ANIP has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in ANIP in the last 90 days.

Loading…

See today’s whale options flow across the market →

ANIP Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲165 buying vs 136 selling
  • ●Shares held by funds -0.3%
  • ▼Funds holding -16
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding294310−5.2%
In funds' top 1003−100.0%
Held by funds–––
New / increased38 / 12750 / 121−3.5%
Reduced / sold out82 / 5487 / 26+20.4%
Put/call ratio1.44––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ANIP institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ANIP is in one of them and how their past ANIP trades turned out.

ANIP in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ANIP in an article yet. Here's the latest on the wider market.

About Ani Pharmaceuticals

ANI Pharmaceuticals is a biopharmaceutical company based in Princeton, New Jersey. It develops, manufactures, and sells prescription medicines in three areas: rare disease treatments, brand name products, and generic drugs. Its rare disease products include Purified Cortrophin Gel and the ILUVIEN and YUTIQ eye implants, which treat conditions such as diabetic macular edema and uveitis. The company makes its products at its own plants in Minnesota and New Jersey and sells them to patients, physicians, and specialty pharmacies.

Headquarters
Princeton, NJ